drugset / Trial / NCT00035906

Research Study in Patients With Persistent Macular Edema

NCT00035906 ↗

Phase 2 Completed 315 enrolled Allergan Oculex Pharmaceuticals · collab
RandomizedParallel-groupTreatment

Summary

The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects. Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision. There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.

Timeline

Start
2001-10
Primary completion
2004-08
Completion
2004-08

Outcome

Met primary endpoint

paper 700 microg (35%) or 350 microg (24%), than observed patients (13%; P<.001 vs 700-microg group; P = .04 vs 350-microg group) PMID 17353400 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 350 ug Intravitreal
Subject Dexamethasone Small molecule 700 ug Intravitreal